Corporate calendar for Cullinan Therapeutics, Inc. (CGEM): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in pat...
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-0.06 | $79M |
| 2026-09-14 | ||
| 2026-09-14 | $144M | |
| 2026-09-14 | $563M | |
| 2026-09-14 | $-0.05 | $3M |
| 2026-09-14 | $0.06 | $3M |
Price
| Price | $20.63 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 1.00 |
Related companies: ADCT · BCYC · CBLL · EHAB · LAB · NMRA · OMER
Explore sector: Healthcare · Biotechnology
More sections of CGEM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks